Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alx Oncology Holdings (ALXO) Common Equity (2019 - 2023)

Alx Oncology Holdings' Common Equity history spans 5 years, with the latest figure at $168.8 million for Q3 2023.

  • For Q3 2023, Common Equity fell 41.19% year-over-year to $168.8 million; the TTM value through Sep 2023 reached $168.8 million, down 41.19%, while the annual FY2022 figure was $263.5 million, 27.43% down from the prior year.
  • Common Equity for Q3 2023 was $168.8 million at Alx Oncology Holdings, down from $212.7 million in the prior quarter.
  • Across five years, Common Equity topped out at $429.8 million in Q4 2020 and bottomed at -$84.4 million in Q2 2020.
  • The 5-year median for Common Equity is $257.7 million (2020), against an average of $207.3 million.
  • The largest annual shift saw Common Equity surged 708.51% in 2020 before it crashed 41.19% in 2023.
  • A 5-year view of Common Equity shows it stood at -$70.6 million in 2019, then soared by 708.51% to $429.8 million in 2020, then dropped by 15.54% to $363.0 million in 2021, then dropped by 27.43% to $263.5 million in 2022, then tumbled by 35.95% to $168.8 million in 2023.
  • Per Business Quant, the three most recent readings for ALXO's Common Equity are $168.8 million (Q3 2023), $212.7 million (Q2 2023), and $240.4 million (Q1 2023).